abrdn European Equity Enhanced Index Fund B AccRegister to Unlock Ratings |
Performance History | 31/03/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 6.8 | 17.3 | -8.3 | 15.6 | 5.6 | |
+/-Cat | -2.6 | 1.8 | 0.5 | 2.1 | -0.6 | |
+/-B’mrk | -1.1 | 0.0 | -0.8 | 0.6 | -1.4 | |
Category: Europe ex-UK Equity | ||||||
Category Benchmark: Morningstar DM Eur xUK TME ... |
Key Stats | ||
NAV 26/04/2024 | GBX 209.66 | |
Day Change | 0.61% | |
Morningstar Category™ | Europe ex-UK Equity | |
IA (formerly IMA) Sector | Europe Excluding UK | |
ISIN | GB00BRJL7X45 | |
Fund Size (Mil) 24/04/2024 | GBP 226.80 | |
Share Class Size (Mil) 25/04/2024 | GBP 174.16 | |
Max Initial Charge | - | |
Ongoing Charge 15/02/2024 | 0.25% |
Investment Objective: abrdn European Equity Enhanced Index Fund B Acc |
To generate growth over the long term (5 years or more) by investing in European equities (company shares). The fund will invest at least 70% in equities and equity related securities that are constituents of the MSCI Europe ex UK Index. The fund will typically invest directly but may also invest indirectly when deemed appropriate in order to meet its objective. Indirect investment may be achieved via derivatives. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Not Disclosed 06/03/2015 | ||
Inception Date 06/03/2015 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI Europe Ex UK NR GBP | Morningstar DM Eur xUK TME NR EUR |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for abrdn European Equity Enhanced Index Fund B Acc | 31/03/2024 |
|
|
Top 5 Holdings | Sector | % |
Novo Nordisk A/S Class B | Healthcare | 5.10 |
ASML Holding NV | Technology | 4.19 |
Nestle SA | Consumer Defensive | 2.84 |
SAP SE | Technology | 2.75 |
Novartis AG Registered Shares | Healthcare | 2.65 |
Increase Decrease New since last portfolio | ||
abrdn European Equity Enhanced Index Fund B Acc |